Regarding association between treatment response and clinicopathologic factor, female gender (P = 0.007), adenocarcinoma histology (P = 0.004) and an EGFR mutation status (P = 0.005) were significantly associated with disease control rate achieved by gefitinib treatment (Table 1). Here, EGFR is linked to adenocarcinoma.